Aurobindo, AstraZeneca ink supply pact

Aurobindo Pharma, has signed a deal with the UK-based AstraZeneca to supply a range of generic drugs. Aurobindo will supply 25 solid dosage and sterile products to be sold in 40 emerging markets, excluding India and China. These products will address therapeutic segments such as anti-infective, cardiovascular system and central nervous system. 

The deal is the second such agreement for the Hyderabad-based drug maker in the past two years. A similar one with US giant Pfizer was signed in March last year. Together, the two deals are expected to produce $350-$500-million revenue next year.